Poolbeg Pharma to present at investor conferences
13 September 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, today announces that members of its management team will be attending four upcoming investor events across September and October.
· Proactive Investors One2One Forum (virtual) on 16 Sep 2021. Registration Link: click here
· Small Company Champion Investor Presentation on 17 Sep 2021 at The Menphys Hub, Bassett Street South, Wigston, Leicester LE18 4PE. Registration Link: click here
· Shares Magazine Investor Webinar (virtual) on 5 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here
· London South East Webinar (virtual) on 19 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here
The above event details may be subject to change. Further information and any updates will be on the events section of the Poolbeg Pharma website.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“Following continuing demand after an oversubscribed AIM listing in July and a share price above the IPO price, I am looking forward to sharing how our capital-light model and a scalable platform for growth will deliver value creation for our shareholders. Poolbeg Pharma is targeting a rapidly expanding market of infectious diseases, which is expected to exceed $250B by 2025. These events will be an opportunity to discuss our attractive, Phase II ready lead asset (POLB 001) tackling the inflammatory response to severe influenza, and our special access to a unique data bank of 20 years of infectious disease data in humans which we will mine to identify new, compelling therapeutics.”
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+353 (0) 1 644 0007
About Poolbeg Pharma
Poolbeg Pharma is a clinical-stage infectious disease pharmaceutical company, with a capital-light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop-shop” for Big Pharma seeking mid-stage products to licence or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest-growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from Open Orphan plc, an industry-leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical-stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.
For more information, please go to www.poolbegpharma.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of the London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing to Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned